Stock Updates

How has Regeneron Pharmaceuticals, Inc. performed recently?

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a large market cap stock with a market cap of 39351.44. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 48.11, a forward P/E of 24.16 and EPS of 7.71. At a stock price of 370.96 (1.34%) it has a dividend yield of *TBA.

REGN

EPS growth for the last five years have been 38.80%, more recently this last year it has grown by 39.50%. The next year growth is going to be about 18.89% and more long-term 18.31% after five years. EPS growth quarter over quarter is 63.00%. Sales growth for the past five years have been 61.30% and sales growth quarter over quarter is 11.70%.

For performance, Regeneron Pharmaceuticals, Inc. the past week has seen a gain of 1.06%. For the last month performance for Regeneron Pharmaceuticals, Inc. is -2.90%. While the last quarter is 2.21% and half year, 1.15%. Finally for the year, performance is -10.35%.

The 52-week high for Regeneron Pharmaceuticals, Inc., is at -18.10%, and for the 52-week low it comes to a value of 14.02%. The 20-day simple moving average is -1.50% and -3.31% for the 200-day simple moving average.

Volatility for the week is at 2.03%, and for the month it is 2.49%. Regeneron Pharmaceuticals, Inc., has a target price of 416.43.

In terms of debt, long term debt/equity is 0.08, and for total debt/equity Regeneron Pharmaceuticals, Inc. has 0.11. The gross margin is 93.80%, while operating margin is 27.40%, the profit margin is 18.40%. The current ratio is 2.6 and the quick ratio is 2.3.

Insider ownership is at 1.40%, with instituitional ownership at 69.90%. Regeneron Pharmaceuticals, Inc. has a payout ratio of 0.00%. With the total shares outstanding coming to 106.08. The shares float is 78.08, with the float short at 3.65%, with short ratio coming to 3.19.

In terms of returns, the return on assets see Regeneron Pharmaceuticals, Inc., get 13.80%, with its returns on investment at 18.20%. Return on equity is 21.30%. So will the investors see the target price of 416.43, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

About the author

Peter Clarke

Leave a Comment